Phase III VALOR Trial of Cytarabine with or without Vosaroxin for Patients with Relapsed/Refractory AML


Phase III VALOR Trial of Cytarabine with or without Vosaroxin for Patients with Relapsed/Refractory AML
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Mikkael A Sekeres, MD, MS (1/20/15)
Ravandi F et al. Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: Results of a phase 3 double-blind randomized controlled multinational study (VALOR). Proc ASH 2014;Abstract LBA-6.

Dr Sekeres is Professor of Medicine and Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio.